Ever since Anavex Life Sciences Corp (OTCMKTS:AVXL) revealed the data of a new report, its share price has been posting strong gains remarkably. However, it consolidated in last trading session and closed at $0.379. The decline of 0.26% came at a share volume of 2.30 compared to average share volume of 1.80 million.

Sigma-1 receptor

The most significant press release by Anavex was issued during late April when it highlighted the review on its Sigma-1 receptor agonists. The review and data appeared in a Scientific Journal known as Neuroscience Letters.

Real-time data

The publication highlighted the real-time trial data which demonstrated the success of sigma-1 receptor in overcoming the harmful effects of microglial inflammation. As per report, after sigma-1 receptor gets activated, it helps in mitigating the negative response caused by Chronic Microglia. The excess of Microglia can result in a number of harmful neurodegenerative diseases.

The significance

The company said that the findings highlighted in the journal were promising and helped establish the base that the sigma-1 receptor possesses power to restrict harmful impact of Chronic Microglia. The review published in the Scientific Journal further indicates the prominent role of Anavex Life lead candidates sigma-1 receptor agonists, particularly ANAVEX 2-73. As of now it is under a Phase II a clinical trial to treat Alzheimer’s disease. Anavex concluded important points from the article that sigma-1 receptor activity could be increased through agonists. It can help to nullify the negative impact of neuro inflammation.

The encouraging results

Anavex found the report data convincing to drive a conclusion that activating sigma-1 receptor have0 a lot of importance in controlling the problems associated with Chronic Microglia. The company’s Chief Executive Christopher U. Missling expressed optimism over the data and was confident that company’s drug ANAVEX 2-73 will successfully reduce negative impact of microglia inflammation.